New York, Nov. 15, 2026 Globe Newswire -- Mesoblast Limited Nasdaq Meso Asx Msb , global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities
Why Is Mesoblast Limited (MESO) Stock Down Today?
Updated Nov 16, 2026 2:29 PM ET · Prev Close $13.27
Session Regime & Catalyst Assessment
68% Signal ConvictionMesoblast Limited Pulling Back 6.03% on 0.29x Relative Volume
Mesoblast Limited (MESO) is pulling back 6.03% (-$0.80) to $12.47 on 0.29x average session volume. Relative to benchmarks, MESO is lagging the S&P 500 by -4.14%. 14-day RSI stands at 39.0, keeping momentum in a bearish regime.
New York, Nov. 15, 2026 Globe Newswire -- Mesoblast Limited Nasdaq Meso Asx Msb , global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities
Price ($12.47) trades relative to 20-day SMA ($13.64) and 50-day SMA ($14.22).
Market & Sector Relative Strength
MESO lagging the S&P 500 by -4.14%Options Flow & Execution Desk
Recent MESO Catalyst Headlines
Verified WireMesoblast Nasdaq Meso reported 115 million in net revenue for fiscal 2026 and said it expects a pivotal trial readout for its experimental chronic low back pain treatment around midyear to the third quarter of calendar 2
Rising refinancing costs in a world hit by a new credit crunch are putting pressure on heavily indebted companies, while investors increasingly favour businesses with cleaner balance sheets and clear leadership. Founder
AI related infrastructure is now driving a large share of global trade, with AI enabling goods responsible for most of the recent growth in worldwide shipments. That kind of structural shift tends to reward fast growing
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $13.64 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (MESO)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishAbout Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory …
Get Instant MESO Catalyst Alerts
Receive an email alert when MESO triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversMESO Session & Catalyst FAQ
Why is MESO stock down today?
Mesoblast Limited (MESO) is pulling back 6.03% (-$0.80) to $12.47 on 0.29x average session volume. Relative to benchmarks, MESO is lagging the S&P 500 by -4.14%. 14-day RSI stands at 39.0, keeping momentum in a bearish regime.
Is MESO stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.29x relative volume (low participation). Our multi-factor model currently rates MESO as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the MESO Buy or Sell Decision Brief →
What is MESO's intrinsic value and expected trading range?
At $12.47, MESO's modeled 1-to-3 session range is $11.78 – $13.16, with a key inflection level at $13.64 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the MESO Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for MESO?
RSI at 39.0 reflects soft below-midline momentum. MESO trades at $12.47 relative to its 20-day SMA ($13.64) and 50-day SMA ($14.22), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.